ParcelBio

Elevated mRNA for transformative medicines.

Y CombinatorWinter 2024ActiveHealthcareTherapeuticsGene TherapySynthetic BiologyBiotechTherapeutics

What they do

Problem

Many mRNA therapies fail to achieve sufficient protein expression and durability to deliver meaningful or curative clinical outcomes.

Solution

ParcelBio’s APEXm™ platform engineers novel RNA domains into mRNA medicines to increase protein expression and extend therapeutic activity.

Who it's for

Biopharmaceutical companies and clinical teams developing mRNA-based treatments for autoimmune disease, oncology, and protein therapeutics.

Founders

David Weinberg

Founder

David is the co-founder and CEO of ParcelBio. He was previously VP of RNA Platform at Orbital Therapeutics / Circ Bio, where he led the development of a circular RNA therapeutics platform. Before that, he was Sr. Director of Molecular Research at Freenome, where he built the multiomics diagnostics platform that enabled a blood test for the early detection of cancer. David obtained his PhD from MIT, was a UCSF Faculty Fellow, and has been honored with Forbes ‘30 Under 30’ and an NIH DP5 Award.

Chris Carlson

Founder

Chris is the co-founder and CSO of ParcelBio. He was previously a scientist at Orbital Therapeutics, where he was the primary contributor on multiple patents regarding stabilization of therapeutic RNAs. Chris obtained his PhD from UCSF where he studied RNA packaging and protection in viruses.